International ClinicsMedical News
International Clinics Newsroom · · 2 min read
Daily

EMA recommends Foundayo (orforglipron), a once-daily GLP-1 tablet for obesity and type 2 diabetes

  • On 16 October 2026 the EMA's human medicines committee recommended authorising Foundayo (orforglipron) in the EU.
  • Orforglipron is a once-daily oral GLP-1 receptor agonist for weight management and type 2 diabetes in adults.
  • In two studies of 4,740 adults, participants lost about 5% to 11% of body weight at 72 weeks versus 2% to 2.5% on placebo.
  • The opinion now awaits a European Commission decision.
European Medicines Agency headquarters in Amsterdam
European Medicines Agency headquarters in Amsterdam Photo: European Medicines Agency
Published:

The European Medicines Agency's human medicines committee (CHMP) recommended on 16 October 2026 that Eli Lilly's Foundayo (orforglipron) be authorised in the European Union. It is a once-daily GLP-1 receptor agonist tablet for weight management and for type 2 diabetes in adults.

Who it is for

For weight management it is used with a healthy diet and physical activity in adults with obesity, or overweight with at least one weight-related health problem. For type 2 diabetes it is used when diet and exercise are not enough, alone when metformin is unsuitable, or with other diabetes medicines.

Also read: Australia's TGA approves the first weight-loss pill, oral semaglutide (Wegovy)

What sets it apart

Orforglipron is a small, non-peptide molecule, so it can be taken by mouth at any time of day, with or without food. Treatment starts at a low dose that is raised gradually. It reduces appetite, increases fullness and lowers blood glucose.

Results

For weight management the recommendation rests on two studies of 4,740 adults: after 72 weeks participants lost about 5% to 11% of body weight depending on dose, versus 2% to 2.5% on placebo. In four diabetes studies of 3,765 adults, HbA1c fell by about 1.2 to 1.9 percentage points. The most common side effects were nausea, vomiting and diarrhoea, mainly during dose increases.

Next step

The CHMP opinion is an intermediate step. The European Commission now decides on EU-wide authorisation, and each member state then sets price and reimbursement.

Sources: European Medicines Agency (EMA), EMA — CHMP meeting highlights, October 2026

This story is relayed from the source named above; responsibility for its content rests with the original source.

FAQ

What is Foundayo (orforglipron)?

Foundayo (orforglipron) is a once-daily oral GLP-1 receptor agonist from Eli Lilly for weight management and type 2 diabetes in adults.

When did the EMA recommend orforglipron?

The EMA's CHMP recommended authorising orforglipron (Foundayo) on 16 October 2026; the final decision rests with the European Commission.

How much weight did people lose on orforglipron?

In two studies of 4,740 adults, people on orforglipron lost about 5% to 11% of body weight at 72 weeks depending on dose, versus 2% to 2.5% on placebo.

What are the common side effects of orforglipron?

The most common side effects of orforglipron are nausea, vomiting and diarrhoea, which occur mostly while the dose is being increased.

Does orforglipron have to be taken on an empty stomach?

No. According to the EMA, orforglipron tablets can be taken at any time of day, with or without food.

How would you rate this story?
3,777
Latest news
A fluoride-free gel that may rebuild tooth enamel, from the University of Nottingham Jackson 5's Marlon Jackson reveals he has lived with prostate cancer for four years Tip of the day: get your flu vaccine early, before winter peaks Every plant-based food in a UK study contained fungal toxins, all within EU guideline levels Tip of the day: spit, don't rinse, after brushing your teeth Energy drinks appear 11 times more often in cardiac arrest reports, preliminary study finds ISAPS global survey: eyelid surgery leads, breast lift grows fastest and filler declines Hippocrates: "Life is short, and Art long" Born on this day: William Beaumont and the hole in a stomach that rewrote digestion Tip of the day: sleep at least 7 hours a night, on a regular schedule
The latest-news bar is closed. You can bring it back any time with the “Latest news” button in the menu.